RoosterBio Launches Products to Streamline & Scale Production of Extracellular Vesicle

To radically simplify processes and increase productivity for researchers, RoosterBio Inc. has launched two bioprocess media products, RoosterCollect™-EV and EV Boost™, that supplement a scalable xeno-free manufacturing process to efficiently produce, collect, and boost human mesenchymal stem/stromal cell (hMSC)-derived exosomes and extracellular vesicles (EVs). By starting with a high-volume hMSC-specific process, customers can now catalyze a complete EV workflow within a tunable platform delivering marked savings in process time – which directly translates to accelerated development programs and cost savings.

Within the regenerative medicine industry, the exosome market is one of the fastest growing segments, exhibiting a compound annual growth rate (CAGR) of over 40%. MSCs are at the forefront of this growth as 50% of all stem cell-derived exosome/EV publications in 2018 were specific to MSCs. A cornerstone to today’s challenges related to therapeutic EV development has been industrializing EV platforms to make them more productive. RoosterBio is addressing the EV productivity challenge in two ways. First, they are helping EV product developers quickly achieve significant cell mass and efficient EV collection using RoosterBio’s cell and bioprocess media kits coupled with RoosterCollect-EV. This solution can be immediately implemented in 2D flask or 3D bioreactor culture systems. Secondly, RoosterBio has invented a patent pending product (EV Boost) designed to stimulate cells to increase EV production – driving massive EV productivity gains without scale up.

RoosterBio’s Founder & Chief Product Officer, Jon A. Rowley, PhD said, “The launch of these two products complement our hMSC bioprocess systems and provide a complete EV production solution enabling our customers to escape the ‘exosome bottleneck’, and rapidly get into the clinic with hMSCderived EVs made with efficient and scalable processes.” He added, “The product, system, and bioprocess are critical. If EV production is the issue, high quality cellular starting materials coupled with scalable processes are the solution.”

Source – PRWeb

Leave a Reply

Your email address will not be published. Required fields are marked *